AU2005226910B2 - Oral matrix formulations comprising licarbazepine - Google Patents

Oral matrix formulations comprising licarbazepine Download PDF

Info

Publication number
AU2005226910B2
AU2005226910B2 AU2005226910A AU2005226910A AU2005226910B2 AU 2005226910 B2 AU2005226910 B2 AU 2005226910B2 AU 2005226910 A AU2005226910 A AU 2005226910A AU 2005226910 A AU2005226910 A AU 2005226910A AU 2005226910 B2 AU2005226910 B2 AU 2005226910B2
Authority
AU
Australia
Prior art keywords
licarbazepine
pharmaceutical
cellulose
use according
swellable substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2005226910A
Other languages
English (en)
Other versions
AU2005226910A1 (en
Inventor
Oskar Kalb
Marie-Christine Wolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0406379A external-priority patent/GB0406379D0/en
Priority claimed from GB0406738A external-priority patent/GB0406738D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2005226910A1 publication Critical patent/AU2005226910A1/en
Application granted granted Critical
Publication of AU2005226910B2 publication Critical patent/AU2005226910B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AU2005226910A 2004-03-22 2005-03-21 Oral matrix formulations comprising licarbazepine Expired - Fee Related AU2005226910B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0406379.8 2004-03-22
GB0406379A GB0406379D0 (en) 2004-03-22 2004-03-22 Organic compounds
GB0406738.5 2004-03-25
GB0406738A GB0406738D0 (en) 2004-03-25 2004-03-25 Organic compounds
PCT/EP2005/002988 WO2005092294A1 (en) 2004-03-22 2005-03-21 Oral matrix formulations comprising licarbazepine

Publications (2)

Publication Number Publication Date
AU2005226910A1 AU2005226910A1 (en) 2005-10-06
AU2005226910B2 true AU2005226910B2 (en) 2009-06-04

Family

ID=34961345

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005226910A Expired - Fee Related AU2005226910B2 (en) 2004-03-22 2005-03-21 Oral matrix formulations comprising licarbazepine

Country Status (16)

Country Link
US (1) US20070196488A1 (enExample)
EP (1) EP1732519A1 (enExample)
JP (1) JP2007529564A (enExample)
AR (1) AR048318A1 (enExample)
AU (1) AU2005226910B2 (enExample)
BR (1) BRPI0509067A (enExample)
CA (1) CA2558787A1 (enExample)
EC (1) ECSP066860A (enExample)
IL (1) IL177826A0 (enExample)
MA (1) MA28527B1 (enExample)
MX (1) MXPA06010810A (enExample)
NO (1) NO20064808L (enExample)
PE (1) PE20051156A1 (enExample)
RU (1) RU2006137330A (enExample)
TW (1) TW200534844A (enExample)
WO (1) WO2005092294A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
AR048672A1 (es) * 2004-03-22 2006-05-17 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
EP2380573B1 (en) * 2005-05-06 2015-02-25 Bial-Portela & CA, S.A. Eslicarbazepine acetate and methods of use
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8372431B2 (en) * 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
EP2683691B1 (en) 2011-03-08 2018-06-06 Jubilant Life Sciences Limited PROCESS FOR THE PREPARATION OF (S)-(+)-10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ[b,f]AZEPINE-5-CARBOXAMIDE AND ESTERS THEREOF BY ENANTIOSELECTIVE REDUCTION OF 10,11-DIHYDRO-10-OXO-5H-DIBENZ[b,f]AZEPINE-5-CARBOXAMIDE
EP2498481A1 (en) 2011-03-09 2012-09-12 Sensirion AG Mobile phone with humidity sensor
JP2013237676A (ja) * 2013-06-26 2013-11-28 Bial-Portela & Ca Sa 酢酸エスリカルバゼピン及び使用方法
EP3957302A1 (en) 2015-12-18 2022-02-23 Jubilant Generics Limited Solid oral dosage forms of eslicarbazepine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
WO1998035681A1 (en) * 1997-02-14 1998-08-20 Novartis Ag Oxacarbazepine film-coated tablets
WO2000001416A1 (en) * 1998-07-07 2000-01-13 Yissum Research Developing Company Of The Hebrew University Of Jerusalem Pharmaceutical compositions containing low-melting waxes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
CA2485932A1 (en) * 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release
CA2494660A1 (en) * 2002-08-06 2004-02-19 Novartis Ag Use of carboxamides for the treatment of tinnitus
AR048672A1 (es) * 2004-03-22 2006-05-17 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
WO1998035681A1 (en) * 1997-02-14 1998-08-20 Novartis Ag Oxacarbazepine film-coated tablets
WO2000001416A1 (en) * 1998-07-07 2000-01-13 Yissum Research Developing Company Of The Hebrew University Of Jerusalem Pharmaceutical compositions containing low-melting waxes

Also Published As

Publication number Publication date
AR048318A1 (es) 2006-04-19
TW200534844A (en) 2005-11-01
WO2005092294A1 (en) 2005-10-06
AU2005226910A1 (en) 2005-10-06
EP1732519A1 (en) 2006-12-20
IL177826A0 (en) 2006-12-31
MA28527B1 (fr) 2007-04-03
US20070196488A1 (en) 2007-08-23
JP2007529564A (ja) 2007-10-25
CA2558787A1 (en) 2005-10-06
RU2006137330A (ru) 2008-05-10
BRPI0509067A (pt) 2007-08-21
NO20064808L (no) 2006-12-15
MXPA06010810A (es) 2006-12-15
PE20051156A1 (es) 2006-02-13
ECSP066860A (es) 2006-11-24

Similar Documents

Publication Publication Date Title
AU777705B2 (en) Pharmaceutical compositions
DK200500297U3 (da) Tamsulosin tabletter med modificeret frigivelse
NZ528738A (en) Composition comprising nateglinide for treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
JP2000511170A (ja) 医薬組成物
AU762829B2 (en) New oral formulation for 5-HT4 agonists or antagonists
AU2005226910B2 (en) Oral matrix formulations comprising licarbazepine
US20060057203A1 (en) Modified release formulations of oxcarbazepine and derivatives thereof
AU2005226909B2 (en) Disintegrating tablets comprising licarbazepine
US10383832B1 (en) Sustained release metoprolol formulations
US20060229261A1 (en) Acarbose methods and formulations for treating chronic constipation
KR20070017335A (ko) 리카르바제핀을 포함하는 경구투여용 매트릭스 제제
WO2005092293A1 (en) Formulations of metformin
KR20070017336A (ko) 리카르바제핀을 포함하는 붕해성 정제
CN1933819A (zh) 包含利卡西平的口服基质制剂
CN1933817A (zh) 包含利卡西平的崩解片
WO2017114597A1 (en) Pharmaceutical dosage forms comprising ((cis)-n-(4-(dimethylamino)-1,4- diphenylcyclohexyl)-n-methylcinnamamide

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee